These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6811355)

  • 41. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE; Matthews DR
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Determination of glibenclamide and puerarin in rat plasma by UPLC-MS/MS: application to their pharmacokinetic interaction study.
    Li N; Deng Y; Wang D; Qiao Y; Li F
    Talanta; 2013 Jan; 104():109-15. PubMed ID: 23597896
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Determination of glibenclamide and its two major metabolites in human serum and urine by column liquid chromatography.
    Rydberg T; Wåhlin-Boll E; Melander A
    J Chromatogr; 1991 Mar; 564(1):223-33. PubMed ID: 1907291
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interindividual variation in the absorption of glibenclamide in man.
    Ikegami H; Shima K; Tanaka A; Tahara Y; Hirota M; Kumahara Y
    Acta Endocrinol (Copenh); 1986 Apr; 111(4):528-32. PubMed ID: 3085419
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics.
    Groop L; Wåhlin-Boll E; Groop PH; Tötterman KJ; Melander A; Tolppanen EM; Fyhrqvist F
    Eur J Clin Pharmacol; 1985; 28(6):697-704. PubMed ID: 3933984
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Post-stenotic coronary blood flow at rest is not altered by therapeutic doses of the oral antidiabetic drug glibenclamide in patients with coronary artery disease.
    Reffelmann T; Klues HG; Hanrath P; Schwarz ER
    Heart; 2002 Jan; 87(1):54-60. PubMed ID: 11751665
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of BTS 67 582, a novel antidiabetic agent, in normal and diabetic rats.
    Jones RB; Dickinson K; Anthony DM; Marita AR; Kaul CL; Buckett WR
    Br J Pharmacol; 1997 Mar; 120(6):1135-43. PubMed ID: 9134227
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Correlations between in vitro dissolution, in vivo bioavailability and hypoglycaemic effect of oral glibenclamide.
    Chalk JB; Patterson M; Smith MT; Eadie MJ
    Eur J Clin Pharmacol; 1986; 31(2):177-82. PubMed ID: 3100314
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preliminary pharmacokinetics of intravenous ciramadol in humans.
    Rosseel MT; Bogaert MG; Oosterlinck W
    Int J Clin Pharmacol Ther Toxicol; 1984 Jun; 22(6):304-6. PubMed ID: 6547699
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-pressure liquid chromatographic assay and pharmacokinetics of HR 810 after intramuscular injection in rabbits.
    Bawdon RE; Lu YS; Brater DC
    Antimicrob Agents Chemother; 1985 Apr; 27(4):436-8. PubMed ID: 3890723
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rapid and specific method for the determination of vancomycin in plasma by high-performance liquid chromatography on an aminopropyl column.
    Hosotsubo H
    J Chromatogr; 1989 Feb; 487(2):421-7. PubMed ID: 2723006
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Serum concentration and kinetics after i.v.-infusion of 3 g lincomycin (author's transl)].
    Adam D; Pätzold J
    Arzneimittelforschung; 1979; 29(1):130-4. PubMed ID: 582106
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Amosulalol, a combined alpha and beta adrenoceptor antagonist: kinetics after intravenous and oral doses.
    Nakashima M; Asano M; Ohguchi S; Hashimoto H; Seki T; Miyazaki M; Takenaka T
    Clin Pharmacol Ther; 1984 Oct; 36(4):436-43. PubMed ID: 6478731
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The pharmacokinetics and oral bioavailability studies of columbianetin in rats after oral and intravenous administration.
    Luo Q; Wang CP; Li J; Ma WF; Bai Y; Ma L; Gao XM; Zhang BL; Chang YX
    J Ethnopharmacol; 2013 Oct; 150(1):175-80. PubMed ID: 23994338
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Determination of ibuprofen in serum by high-performance liquid chromatography and application to ibuprofen disposition.
    Kearns GL; Wilson JT
    J Chromatogr; 1981 Nov; 226(1):183-90. PubMed ID: 7320142
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improved effect of glibenclamide on administration before breakfast.
    Sartor G; Lundquist I; Melander A; Scherstén B; Wåhlin-Boll E
    Eur J Clin Pharmacol; 1982; 21(5):403-8. PubMed ID: 6804245
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
    Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
    Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2.
    Zhang Y; Hua Y; Benbrook DM; Covey JM; Dai G; Liu Z; Chan KK
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):561-9. PubMed ID: 16534614
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Validation of an HPLC method for the determination of scutellarin in rat plasma and its pharmacokinetics.
    Hao X; Cheng G; Sun J; Zou M; Yu J; Zhang S; Cui F
    J Pharm Biomed Anal; 2005 Jun; 38(2):360-3. PubMed ID: 15925232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.